Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion announced that its compensation committee granted stock options to one new employee on November 1, 2024. The grant includes options to purchase 6,500 shares of common stock, which will vest quarterly over four years at a rate of 1/16. The award was made under Biomea's 2023 Inducement Equity Plan and granted as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Biomea Fusion ha annunciato che il suo comitato per la compensazione ha concesso opzioni su azioni a un nuovo dipendente il 1° novembre 2024. La concessione include opzioni per acquistare 6.500 azioni ordinarie, che matureranno trimestralmente per quattro anni a un tasso di 1/16. Il premio è stato conferito nell'ambito del Piano di Induzione Equity 2023 di Biomea ed è stato concesso come incentivo all'assunzione in conformità con la Regola 5635(c)(4) del Nasdaq.
Biomea Fusion anunció que su comité de compensación otorgó opciones de acciones a un nuevo empleado el 1 de noviembre de 2024. El otorgamiento incluye opciones para comprar 6,500 acciones ordinarias, que se concederán trimestralmente durante cuatro años a una tasa de 1/16. El premio se otorgó bajo el Plan de Inducción de Capital 2023 de Biomea y se concedió como un incentivo para el empleo de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Biomea Fusion은 보상 위원회가 2024년 11월 1일에 새로운 직원에게 주식 옵션을 부여했다고 발표했습니다. 이 부여는 6,500주의 보통주를 구매할 수 있는 옵션을 포함하며, 향후 4년 동안 분기별로 1/16의 비율로 확정됩니다. 이 상은 Biomea의 2023 유도 자본 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유도를 위한 것입니다.
Biomea Fusion a annoncé que son comité de rémunération a accordé des options d'achat d'actions à un nouvel employé le 1er novembre 2024. L'octroi comprend des options pour acheter 6 500 actions ordinaires, qui seront acquises trimestriellement sur quatre ans à un taux de 1/16. La récompense a été faite dans le cadre du Plan d'Induction des Actions 2023 de Biomea et accordée comme incitation à l'emploi conformément à la règle de cotation 5635(c)(4) de Nasdaq.
Biomea Fusion gab bekannt, dass sein Vergütungsausschuss einem neuen Mitarbeiter am 1. November 2024 Aktienoptionen gewährt hat. Die Gewährung umfasst Optionen zum Kauf von 6.500 Aktien des Stammkapitals, die über einen Zeitraum von vier Jahren vierteljährlich mit einer Rate von 1/16 fällig werden. Die Auszeichnung wurde im Rahmen des 2023 Inducement Equity Plans von Biomea gewährt und als Anreiz für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4) vergeben.
- None.
- None.
REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on November 1, 2024, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 6,500 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
FAQ
How many shares were granted in Biomea Fusion's (BMEA) November 2024 inducement grant?
What is the vesting schedule for Biomea Fusion's (BMEA) November 2024 stock option grant?
Under which plan were Biomea Fusion's (BMEA) November 2024 inducement grants made?
